Intravitreal injection of pegaptanib sodium for proliferative diabetic retinopathy

British Journal of Ophthalmology

Volumn 93, Issue 11, 2009, Pages 1474-1478

  Gonzalez V H ^a   Giuliari, G P ^a   Banda, R M ^a   Guel, D A ^a  

^a Valley Retina Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB;

ADULT; ANTIANGIOGENIC THERAPY; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG SAFETY; EPIRETINAL MEMBRANE; FEMALE; HUMAN; INTRAOCULAR HEMORRHAGE; IRITIS; LASER COAGULATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA HOLE; RETINA NEOVASCULARIZATION; SUBCONJUNCTIVAL HEMORRHAGE; THICKNESS; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; LASER COAGULATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION;

EID: 70350469069     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.155663     Document Type: Article

References (25)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-851
2. Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-563 (Pubitemid 38456292)
3. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005;6:511-524 (Pubitemid 40916276)
4. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005;40:352-368 (Pubitemid 40942262)
5. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-1828
6. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450 (Pubitemid 24307211)
7. Boulton M, Foreman D, Williams G, et al. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998;82:561-568
8. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-489 (Pubitemid 36976059)
9. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intracellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000;156:1733-1739 (Pubitemid 30646710)
10. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5:123-132
11. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-1757
12. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-28 (Pubitemid 43021723)
13. Anon. Diabetic Retinopathy Study. Report Number 6. Design, methods, and baseline results. Report Number 7. A modification of the Airlie House classification of diabetic retinopathy. Invest Ophthalmol Vis Sci 1981;21:1-226.
14. Early Treatment Diabetic Retinopathy Study Research Group. ETDRS report no. 1: photocoagulation for diabetic macular edema. Arch Ophthalmol 1985;103:1796-1806
15. Early Treatment Diabetic Retinopathy Study Research Group. ETDRS report no. 2: treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology 1987;94:761-774
16. The Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. Int Ophthalmol Clin 1987;274:254-264
17. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical applications of Diabetic Retinopathy Study. DRS Report number 8. Ophthalmology 1981;88:583-600.
18. de Laey JJ. Complications of photocoagulation for diabetic retinopathy. Diabete Metab 1993;19:430-435
19. Kleiner RC, Elman MJ, Murphy RP, et al. Transient severe visual loss after panretinal photocoagulation. Am J Ophthalmol 1988;106:298-306. (Pubitemid 18220909)
20. Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990;97:503-510 (Pubitemid 20108457)
21. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309 (Pubitemid 20066716)
22. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995;1:182-193
23. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538-1544
24. Usui T, Ishida S, Yamashiro K, et al. VEGF 164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci 2004;45:368-374
25. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-1312 (Pubitemid 20066717)